Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +60

Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock

AI-generated analysis

πŸ“ˆ Gilead Sciences (NASDAQ: GILD) ranks 4th on a list of the 14 best defensive stocks currently recommended for investors.

πŸ’Š The company has transitioned away from volatile COVID-19 revenue as it relies heavily on its HIV and oncology pipelines.

πŸ›‘οΈ Gilead's dominant position in the HIV market acts like a utility, generating predictable cash flow unaffected by economic cycles.

πŸ’° The HIV portfolio generated approximately $20.8 billion in 2025, providing high-visibility non-discretionary earnings.

⏳ CFO Andrew Dickinson noted at the Barclays Healthcare Conference that patent exclusivity won't expire until 2036.

πŸ“ˆ Yeztugo, a twice-yearly HIV prevention therapy, is expected to generate $800 million in sales during 2026.

🏦 The stock is a favorite for income-focused funds following the board's decision to raise the quarterly dividend to $0.82 per share in February.

πŸ“‰ As of April, Gilead's forward dividend yield stands at approximately 2.4%.

πŸ’Ό Management guidance projects non-GAAP EPS between $8.45 and $8.85 for the full year 2025.

πŸ”¬ Diversification into oncology now accounts for roughly 12% of total revenue, with products like Trodelvy seeing double-digit growth.

🌱 Cell therapies within the oncology portfolio contribute to a growth kicker on top of the defensive HIV base.

⚠️ The article suggests that while GILD is a strong investment, certain AI stocks may offer greater upside potential.

πŸ“° Readers are directed to a free report on undervalued AI stocks benefiting from tariff trends and onshoring.

πŸ’Ό Disclosure states that there is no conflict of interest for the author regarding the content provided.

Bullish Signals
  • Gilead Sciences Inc. (NASDAQ:GILD) ranks 4th on the list of 14 Best Defensive Stocks, highlighting its strong position as a defensive investment.
  • The company's core business in HIV provides high-visibility, non-discretionary earnings that are unaffected by broader economic cycles.
  • Gilead's HIV portfolio generated $20.8 billion in 2025, demonstrating significant revenue stability and strength.
  • Patients rarely switch treatments once stabilized, creating a highly predictable cash flow similar to a utility company.
  • CFO Andrew Dickinson confirmed that Gilead faces no major loss of exclusivity until 2036, offering a rare safety runway in the pharma sector.
  • Yeztugo, the first twice-yearly HIV prevention therapy, is expected to hit $800 million in sales in 2026.
  • In February, the board raised the quarterly dividend to $0.82 per share, marking another year of consecutive growth for income-focused investors.
  • The forward dividend yield stands at approximately 2.4%, backed by healthy non-GAAP EPS guidance of $8.45–$8.85 for the full year.
  • Oncology now accounts for about 12% of total revenue and is diversifying the company's risk across different therapeutic areas.
  • Products like Trodelvy and cell therapies in the oncology segment are seeing double-digit growth, providing a growth kicker on top of the defensive HIV base.
Full Analysis
Gilead Sciences, Inc. (NASDAQ:GILD) ranks fourth on a list of defensive stocks, appealing to investors seeking stability amid economic uncertainty. The pharmaceutical giant has successfully transitioned from reliance on volatile COVID-19 treatment revenue generated by Veklury toward a core business anchored in HIV and an expanding oncology pipeline. Gilead’s dominance in the HIV market is characterized as having utility-like qualities because its treatments are life-sustaining, creating non-discretionary demand that remains unaffected by broader economic cycles. The company's HIV portfolio alone generated $20.8 billion in 2025, while patients typically stay on their current treatment once stabilized, ensuring highly predictable cash flow. Financial strength and shareholder returns are highlighted as key investment drivers, with the stock being a favorite for income-focused funds due to its aggressive cash return strategy. In February, Gilead's board raised the quarterly dividend to $0.82 per share, continuing a streak of consecutive growth, while the forward dividend yield stands at approximately 2.4% as of April. This yield is supported by robust non-GAAP EPS guidance ranging from $8.45 to $8.85 for the full year. The company's long-term safety profile is further reinforced by a lack of major patent exclusivity loss until 2036, a runway noted by CFO Andrew Dickinson during the Barclays Healthcare Conference in March as providing rare security in the pharma sector. Additionally, Yeztugo, Gilead's first twice-yearly HIV prevention therapy, is expected to reach $800 million in sales by 2026. Beyond its stable HIV base, Gilead has diversified into oncology over the last five years, which now contributes approximately 12% of total revenue and provides a growth kicker alongside its defensive core. Oncology products such as Trodelvy and various cell therapies are reported to be seeing double-digit growth, diversifying risk across different therapeutic areas. While acknowledging Gilead's potential as an investment, the article notes that certain AI stocks may offer greater upside potential with less downside risk, particularly those benefiting from Trump-era tariffs and the onshoring trend, directing interested readers toward a free report on short-term AI stocks. The summary highlights specific figures including $20.8 billion in 2025 HIV portfolio revenue, a 2036 patent expiry date, a $0.82 quarterly dividend, an approximate 2.4% forward yield, and oncology revenue at 12%. The article also mentions anticipated $800 million sales for Yeztugo in 2026 and full-year non-GAAP EPS guidance between $8.45 and $8.85. Despite the defensive attributes of Gilead Sciences, the text suggests investors may consider AI stocks for higher growth potential depending on market conditions and geopolitical factors like tariffs.